Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

Transmission electron micrograph of HIV-1 virus particles from infected H9 cells, produced in cell culture. The particles exhibit two stages of replication: the two “arcs” are immature ...

An Automated Bioinformatics Pipeline Informing Near-Real-Time Public Health Responses to New HIV Diagnoses in a Statewide HIV Epidemic. Viruses 15 (737). doi:10.3390/v15030737 ...

Scientists found a way to make the HIV virus visible, potentially laying the groundwork for ways to banish it from the body altogether. ... Image by Getty / Futurism. Read This Next.

Engineered virus-like particles can outcompete HIV in the body, potentially offering long-term viral suppression after a single dose, a monkey study suggests. Skip to main content Open menu Close menu ...

Addendum: On June 19, 2025, Sundquist received the Warren Alpert Foundation Prize, which recognizes work that advances the understanding or treatment of human disease. On June 18, 2025, lenacapvir ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.